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Abstract
In this study we set out to investigate whether anti PDL1 or PD–1 treatment targeting the
immune system could be used against multiple myeloma. DCs are important in regulating T
cell responses against tumors. We therefore determined PDL1 and PDL2 expression on
DC populations in bone marrow of patients with plasma cell disorders using multicolour
Flow Cytometry. We specifically looked at CD141+ and CD141- myeloid and CD303+ plas-
macytoid DC. The majority of plasma cells (PC) and DC subpopulations expressed PDL1,
but the proportion of positive PDL1+ cells varied among patients. A correlation between the
proportion of PDL1+ PC and CD141+ mDC was found, suggesting both cell types could
down-regulate the anti-tumor T cell response.
Introduction
Multiple myeloma is an incurable cancer and new therapies are urgently needed. In some
advanced cancers encouraging results have been obtained after treating patients with anti
PDL1 or PD–1 therapy. PD–1 (Programmed cell death–1, CD279) will, when present on T-
and NK-cells, inhibit T-cell effector functions after engagement through its ligands PDL1 or
PDL2 [1]. Thus, the rationale behind treatment with humanized anti PDL1 or PD–1 antibody
therapy such as Nivolumab and Pidilizumab is to block this ligation in vivo [2]. Many tumors
express PDL1. This molecule can constrain anti-cancer immune responses [1,3]. Although not
detected on normal PC, myeloma cell lines and primary myeloma cells in the bone marrow up-
regulate PDL1, and its ligand PD–1 is found on a proportion of T-cells in myeloma patients
[4–7]. Although anti PD–1 treatment alone have so far not been effective [8], It is still impor-
tant to characterize the expression of PDL1 and PDL2 on subsets of leukocytes to verify
whether there are differences between myeloma patients. If this is the case, only subgroups of
patients may respond to the therapy. In addition, we would like know whether responses to
PD1 treatment could be restricted to patients with tumor cells expressing PDL1 [9].
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Although PDL1+ tumors can suppress T and NK cell functions, other cells in the microenvi-
ronment may be equally important. Two papers describing expression of PDL1 on PC and
pDC in myeloma were recently published [6,7]. However, the expression of PDL1 on subtypes
of DC in tumors is so far largely undefined. DCs are superior to monocytes in controlling T-
cell responses [10]. Four main populations of DCs have been identified in the blood and
peripheral organs of humans [11]. Inflammatory DCs are similar to monocytes; they express
CD11c and MHC class II, but not the myeloid DC marker CD1c. Their role in the regulation of
T cell responses in humans is unclear and was therefore left out of the analysis. CD303+ plas-
macytoid DC (pDC), are rapidly recruited to sites of inflammation where they produce cyto-
kines and influence the local immune response [12]. CD1c+ myeloid DCs (mDC), which are
most effective at controlling T cells, have two sub-types; CD1c+CD141+ DC (CD141+ DC), and
CD1c+CD141- DCs (CD141- DC) [13,14]. The CD141+DCs control the CD8+ T cell responses
and the CD141-DCs regulate the CD4+ T cell responses [11]. In this study we set out to deter-
mine the PDL1 and PDL2 expression on these 3 DC populations.
Materials and Methods
Bone marrow samples
Bone marrow cells and blood were collected in sodium heparin (Wockhardt,Wrexham, UK)
from the iliac crest from patients suffering from multiple myeloma. The patients were regis-
tered in the Norwegian Myeloma Biobank and enrolled in the study. The study was approved
by the Regional Ethics Committee (REK 2011–2029). The donors were classified as healthy,
MGUS or multiple myeloma according to the International MyelomaWorking Group
(IMWG) criteria [15]. Patient’s data is shown in table in Supporting Information (S1 File).
Samples were obtained after written consent. Bone marrow PC percentage was determined in
May Grunwald Giemsa stained smears as part of standard diagnostic procedures.
Antibodies
Anti-human CD141FITC (AD5-14H12), (CD3 (SK7), CD19 (SJ25C1), CD138 (MI15), CD56
(CMSSB), CD15 (VIM6C)) all PE conjugated, HLADRV450 (L234), CD45V500 (HI30),
CD38PE-Cy7 (HIT2), CD19APCCy7 (SJ25C1) was obtained (BD Biosciences, Stockholm,
Sweden). CD34PE (4H11), CD235aPE (HIR2), CD11cAlexa Flour 700 (B-ly6), CD1cPECy7
(L161), CD273APC (MH18), CD274APC (MIH1) and human FcReceptor binding inhibitor
was obtained (eBioscience,San Diego,CA,USA), and CD303 PerCpPECy 5.5 (201A) were from
BioLegend, San Diego,CA, USA. FACS lysing buffer was obtained from BD.
Flow Cytometry
Un separated bone marrow cells were stained with a cocktail of antibodies against human
CD141 lineage (CD3, CD19 CD15 CD56, CD138, CD34, and CD235a, CD45, HLADR,
CD11c, CD303, CD1c and CD274 or CD273 for 30 min on ice after 20 min incubation with
human Fc Receptor binding inhibitor. RBCs were lysed and cells fixed after staining. Flow
cytometry was performed using LSR II (BD Biosciences, San Jose, CA, USA) with FACS Diva
software (BD Biosciences). Samples were analysed with FlowJo 7.6 (TreeStar, Ashland, OR,
USA). For the analysis of the mixed monocytes and DC populations, gates were set on live cells
with forward and side scatter and doublets were gated out. Lineage and CD45- were excluded
and % PDL1 (CD274) or PDL2 (CD273) were determined on the gated CD11c+, HLA DR+
cells. Some of the patients also donated peripheral blood for this study.
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PLOS ONE | DOI:10.1371/journal.pone.0139867 October 7, 2015 2 / 8
Competing Interests: The authors declare no
competing financial interest.
Myeloma cells were stained in a separate panel with CD19, CD138, CD38, CD45 and
CD274 antibodies. Gates were set on FSC and SSC and CD19+ cells were excluded. Myeloma
cells were identified as CD19-CD38+ cells. There was a variation in the expression of CD138
and CD45 on the CD19-CD38+ myeloma cells amongst the patients.
Statistical Analysis
Tests were performed using Graph Pad Prism 5 software. Correlations were determined using
Spearman’s Test. Comparisons between groups were done with MannWhitney. Significance
was determined as p< 0.05. We chose to correlate % PDL1 expression with % plasma cell from
the stained smears since bone marrow biopsy and ISS score were not available for all patients
in this study.
Results
PDL1 expression in myeloma bone marrow
In this study we used flow cytometry to determine the expression of PDL1 and PDL2 on unsepa-
rated bone marrow and blood cells from patients with multiple myeloma. We chose to use
unseparated bone marrow and blood samples because cell isolation procedures may affect sur-
face expression of the markers. First, we determined the fractions of PDL1+ and PDL2+ PC and
DC and monocytes in bone marrow aspirates. For myeloma cells, bone marrow cells were
stained with anti CD45, CD19, CD38 and CD138, as well as PDL1 (CD274), or PDL2 (CD273),
as described in Material and Methods and in supplementary information (Fig A in S2 File) PCs
were identified as CD19-, CD38high cells since staining with anti-CD45 and CD138 varied (data
not shown). Patients with more than 5% PDL1+ PCs were defined as PDL1 positive [2]. Ten out
of fourteen patients (71%) had PDL1+ myeloma cells. There was, however, variation in the
abundance of PDL1+ PCs among the patients, ranging from 5% to 96% positive PCs (Fig 1A).
The proportion of PDL1+ PCs did not increase with tumor load (Fig 1B), suggesting that PDL1
expression is not determined directly by the tumor burden, but rather that it is the bone marrow
microenvironment that regulates PDL1 expression.
Next we measured the proportion of PDL1 and PDL2 expressing monocytes/DCs. As both
monocytes and DCs express MHC class II and CD11c [11], cells were stained with a cocktail of
antibodies against lineage cells (CD138, CD56, CD34, CD235a, CD19, CD15 and CD3), CD45,
HLADR, CD11c and PDL1 (CD274) or PDL2 (CD273). Briefly, gates were set on live cells,
CD45+ and lineage negative cells and a dot plot of CD11c and HLADR staining of such gated
cells is shown (Fig B in S2 File). The majority of patients -71% (10/14) were PDL1+; i.e. had
more than 5% PDL1+ cells. The proportion of PDL1+ monocytes/DCs varied among patients
from 6% to 58% (Fig 1C). Most patients with high a proportion of PDL1+ PC also had a high
proportion of PDL1+ monocytes/DCs (Fig 1D), although there was no significant correlation
between high expression on PCs and monocytes/DCs. Interestingly, two patients with no
PDL1 on their PCs had PDL1+ (>5%) monocytes/DCs.
The blood monocytes/DCs from healthy donors expressed no PDL1 (data not shown). Fur-
thermore, no PDL2 positive PCs or monocytes /DCs were detected (Figs C and E in S2 File and
data not shown), suggesting that PDL2 expression is not important for attenuating T-cell
responses in myeloma bone marrow.
PDL1 expression on DC subtypes in myeloma bone marrow
In line with earlier reports, we found PDL1 expression on pDCs [7]. Thus, 81% (13/16)
of patients had more than 5% positive pDC (Fig 2). Interestingly, high proportions of
PDL1 Expression, on DCs and Myeloma Cells
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PDL1+CD141+DCs were detected in the patients’ bone marrow (Fig 2B–2C and 2H–2I).
Thus, the majority, 81% (17/21) had PDL1+CD141+ DC. In contrast, only 48% (10/21) of the
patients had PDL1+ CD141- DCs. This suggested that PDL1 expression on CD141+ DCs
could attenuate the activity of tumor reactive T-cells.
Again, there were variations in the proportion of PDL1+ DCs among the patients (Fig 2B,
2E and 2H). Furthermore, we found no significant correlation between % PC (i.e. tumor load),
and proportion of any of the PDL1+ DC populations (Fig F in S2 File). PDL1 is known to be
up-regulated on DCs in response to inflammatory stimuli [16,17]. We also found that patients
Fig 1. Expression of PDL1 on PC andmonocytes in myeloma bonemarrow. (A) PDL1 on plasma cells: Bone marrow cells were stained with antibodies
against CD45, CD138, CD38, CD19, and CD274 (PDL1). Gates were set on FSC and SSC and doublets and CD19+ cells were excluded. Gating strategy is
shown in Fig A in S2 File. The distribution of % PDL1+ PC in the bone marrow of patients (n = 14) is shown. (B) Proportion of PDL1+ PC does not increase
with tumor load. The % PDL1+ gated CD38+CD19- PC versus% bone marrow plasma cells is plotted. Each dot represents one patient. P values were
calculated from a Spearman’s test (n = 14). (C) PDL1 on monocytes and DCs: Bone marrow cells were stained with antibodies against lineage (CD3, CD19,
CD56, CD138, CD15, CD34, and CD235a), CD45, HLADR, and CD11c. The gating strategy is shown in Supplementary S1B Fig. Gates were set on FSC
and SSC, doublets excluded, and gates further set on lineage- CD45+cells. Figure shows distribution of % PDL1+monocytes/DC in the bone marrow of
patients (n = 14). (D) Correlation of % PDL1+ PC and monocytes/DC; % PDL1+CD11c+DR+ monocytes/DC versus % PDL1+CD38+CD19- plasma cells is
plotted. Each dot represents one patient. P value was calculated from a Spearman’s test.
doi:10.1371/journal.pone.0139867.g001
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with high proportions of PDL1+ PCs had many PDL1+ CD141+ DCs (Fig 2C), suggesting that
agents responsible for the PDL1 up-regulation were similar for both cell populations.
The PDL1+ DCs were confined to the bone marrow (Fig 2), as only a small fraction of the
myeloma patients had PDL1+ DCs in the blood (2/8 patients had PDL1+ blood CD141+ DCs,
1/8 had PDL1+ CD141- DCs), indicating that the PDL1+ DCs accumulate in the organ affected
by malignant cells.
Fig 2. DC subtypes express PDL1 in myeloma bonemarrow. Bone marrow and blood were stained with antibodies against CD141, lineage (CD3, CD19,
CD56, CD138, CD15, CD34, and CD235a), CD45, HLADR, CD303, CD1c, and CD11c. The gating strategy is shown in Fig D in S2 File). Three DC
populations were analysed; CD141+ (CD141+DC) (panels A-C), CD141- (CD141-DC) (panels D-F), and CD303+DC (pDC) (panels G-I). PDL1 staining on
one representative patient (panels A, D, G). Fluorescence minus one (FMO), (dotted line), was used as negative control and the percentage indicates PDL1+
cells of the gated DC population. Panels B, E, and H show percentage of PDL1+ cells within the (B) CD141+ DC, (E) CD141- DC and (H) CD303+ pDC
populations in the bone marrow (n = 19), blood (n = 8) from patients, or blood from age matched (median age 61) healthy controls (n = 9). (median age of
patients 61). Statistical analysis was performed with MannWhitney Test. Panels C, F, and I show concomitant expression levels on bone marrow DC
subtypes and plasma cells in individual patients. Each dot represents one patient. P values were calculated from Spearman’s tests.
doi:10.1371/journal.pone.0139867.g002
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Discussion
Since dendritic cells (DC) are important in regulating T cell responses, we determined PDL1
and PDL2 expression on CD141+ and CD141- myeloid (mDCs) and CD303+ plasmacytoid
dendritic cells (pDCs), as well as on plasma cells (PC) in the blood and bone marrow in groups
of patients with MGUS (monoclonal gammopathy of undetermined significance) and multiple
myeloma. None of the patients expressed PDL2, but PDL1 was found on the majority of PC
and DC subpopulations in the bone marrow. The proportion of PDL1+ cells varied among
patients. Interestingly, there was a positive correlation between the proportion of PDL1+ PC
and CD141+ mDC suggesting that both cell types could inhibit the anti-tumor T cell response.
It was shown previously that PDL1 expression on pDCs was important for regulation of T cell
responses in myeloma patients [7]. We found that CD141+DCs also expressed PDL1, which is
important as these cells control the tumor-specific cytotoxic T cell responses. We propose that
myeloma patients may benefit from anti PD–1/PDL1 treatment. However, it may be necessary
to investigate PDL1 expression on dendritic cells in addition to plasma cells to identify patients
who may benefit from the treatment. The myeloma patients expressed PDL1 in bone marrow
but not in peripheral blood, suggesting that factors present in the tumor environment is impor-
tant for PDL1 expression. The expression of PDL1 on DCs and myeloma cells may be equally
important in attenuating anti tumor immunity. It is not known if there is a threshold of PDL1
expression in the tumor or its microenvironment for attenuating anti-tumor activity. At least 6
clinical studies targeting PDL1 or PD–1 in multiple myeloma have recently been launched
(www.clinicaltrials.gov/). Some results were published from one of these studies (reported at
ASH 2014). Although no objective response was observed in this study, 67% of the patients
had stable disease. Further analysis of the PDL1 expression as shown here may be beneficial in
evaluating the response to .PD1 treatment in multiple myeloma.
Supporting Information
S1 File. Patient information. The patients were classified according to the International Mye-
lomaWorking Group (IMWG) criteria. Where limited sample volume was available only part
of the analysis was performed.
ND: not done, NA: not applicable
(DOCX)
S2 File. Gating strategy of plasma cells and dendritic cells. (A) CD38 and CD138 expression
on plasma cells: Unseparated bone marrow cells were stained with a panel of antibodies against
CD45, CD138, CD38, CD19, and CD274 (PDL1) before analysis. Gates were set on FSC and
SSC and doublets and CD19+ cells were excluded. Dot plot of CD138 and CD38 staining of a
patient who expressed CD138 is shown. Histogram shows PDL1 expression of the gated cells.
FMO (dotted line) was used as negative control and the percentage indicates PDL1+ cells of
the gated population. (B) Staining of monocytes/DC: Unseparated bone marrow cells were
stained with a cocktail of antibodies against, lineage (CD3, CD19, CD56, CD138, CD15, CD34,
and CD235a), CD45, HLADR. and CD274 (PDL1) or CD273(PDL2). Briefly, gates were set on
FSC and SSC, doublets were excluded, and gates were further set on lineage- CD45+cells (left
panel) and a gate was then set on CD11c and HLA DR double positive cells (right hand panel).
Histogram shows PDL1 expression of the gated cells. FMO (dotted line) was used as negative
control and the percentage indicates PDL1+ cells of the gated population. (C) Histogram of
PDL2 expression on CD45-CD38+ bone marrow plasma cells. FMO (dotted line) was used as
negative control and the percentage indicates PDL1+ cells of the gated population. (D) Gating
strategy for subgroups of DCs: Unseparated blood and bone marrow cells as indicated were
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stained with a cocktail of antibodies against CD141, lineage (CD3, CD19, CD56, CD138,
CD15, CD34, and CD235a), CD45, HLADR, CD303, CD1c, and CD11c and CD274 (PDL1)
and analysed on an LSR II Flow cytometer. Briefly, gates were set on FSC and SSC, doublets
were excluded, and gates were further set on lineage- CD45+cells, and a gate was then set on
CD11c and HLA DR double positive cells, before the CD1c and CD141, and the CD1c and
CD303 profiles are shown. (E) i. PDL2 expression on monocytes/dendritic cells. Histogram of
PDL2 (CD273) staining of CD11c+ HLA DR+ gated monocyte/DC population in the bone
marrow of a representative patient. The dotted line shows the negative control as in S1C Fig. ii.
Histogram of in vitro cultured DC from PBMC. Monocytes were isolated from PBMC by
adherence and cultured with 40 ng/ml GM-CSF (R&D) and 100ng/ml IL4 (R&D) for 7 days
before adding 10ng/ml LPS (InVivogen) for 4 hrs. The dotted line shows isotype control. (F)
Proportions of PDL1+ DCs do not increase with tumor load. These figures show the percent
PDL1+ versus % PC (May Grunwald Giemsa stain) of all 3 DC populations. Each dot repre-
sents a patient. P value was calculated from a Spearman’s test.
(PDF)
Acknowledgments
We thank Lill Anny Grøseth and Solveig Kvam for collecting samples. The study was approved
by the Regional Ethics Committee (REK 2011–2029), and we are grateful to the patients partic-
ipating in the study. The work was supported by K.G. Jebsen Foundation for Medical Research,
The Cancer Society of Norway, The Regional Health Research Foundation, and The Research
Council of Norway (Grant no. 223255/F50)
Author Contributions
Conceived and designed the experiments: AMS TS AS. Performed the experiments: AMS
NNM EF. Analyzed the data: AMS EF EHR. Contributed reagents/materials/analysis tools: EF
AW EHR. Wrote the paper: EF TS AW AS EHR.
References
1. Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD–1 and its ligands in tolerance and immunity.
Annu Rev Immunol 26: 677–704. doi: 10.1146/annurev.immunol.26.021607.090331 PMID: 18173375
2. Nguyen LT, Ohashi PS (2015) Clinical blockade of PD1 and LAG3—potential mechanisms of action.
Nat Rev Immunol 15: 45–56. doi: 10.1038/nri3790 PMID: 25534622
3. Quezada SA, Peggs KS (2013) Exploiting CTLA–4, PD–1 and PD-L1 to reactivate the host immune
response against cancer. Br J Cancer 108: 1560–1565. doi: 10.1038/bjc.2013.117 PMID: 23511566
4. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, et al. (2007) Plasma cells frommultiple
myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma}
and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110: 296–304. PMID:
17363736
5. Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, et al. (2013) Marrow stromal cells
induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple mye-
loma. Leukemia 27: 464–472. doi: 10.1038/leu.2012.213 PMID: 22828443
6. Paiva B, Azpilikueta A, Puig N, Ocio EM, Sharma R, et al. (2015) PD-L1/PD–1 presence in the tumor
microenvironment and activity of PD–1 blockade in multiple myeloma. Leukemia.
7. Ray A, Das DS, Song Y, Richardson P, Munshi NC, et al. (2015) Targeting PD1-PDL1 immune check-
point in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma
cells. Leukemia.
8. Lesokhin AM, Ansell, S.M., Armand, P., Scott, E.C., Halwani, A., Gutierrez, M., Millenson, M.M.,
Cohen, A.D., Schuster, S.J., Lebovic, D., Dhodapkar, M.V., Avigan, D., Chapuy, B., Ligon, A.H., Scott
J. Rodig, S.J., Cattry, D., Zhu, L., Grosso, J.F., Kim, S.Y., Shipp, M.A., Borrello, I., and Timmerman,J.
PDL1 Expression, on DCs and Myeloma Cells
PLOS ONE | DOI:10.1371/journal.pone.0139867 October 7, 2015 7 / 8
(2014) Preliminary Results of a Phase I Study of Nivolumab (BMS–936558) in Patients with Relapsed
or Refractory Lymphoid Malignancies 56th ASH Annual Meeting and Exposition.
9. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, et al. (2013) Nivolumab plus ipilimumab in
advanced melanoma. N Engl J Med 369: 122–133. doi: 10.1056/NEJMoa1302369 PMID: 23724867
10. Steinman RM, Banchereau J (2007) Taking dendritic cells into medicine. Nature 449: 419–426. PMID:
17898760
11. Collin M, McGovern N, Haniffa M (2013) Human dendritic cell subsets. Immunology 140: 22–30. doi:
10.1111/imm.12117 PMID: 23621371
12. Reizis B, Bunin A, Ghosh HS, Lewis KL, Sisirak V (2011) Plasmacytoid dendritic cells: recent progress
and open questions. Annu Rev Immunol 29: 163–183. doi: 10.1146/annurev-immunol-031210-101345
PMID: 21219184
13. Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, et al. (2010) Characterization of human
DNGR–1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp
Med 207: 1261–1271. doi: 10.1084/jem.20092618 PMID: 20479117
14. Crozat K, Guiton R, Guilliams M, Henri S, Baranek T, et al. (2010) Comparative genomics as a tool to
reveal functional equivalences between human and mouse dendritic cell subsets. Immunol Rev 234:
177–198. doi: 10.1111/j.0105-2896.2009.00868.x PMID: 20193019
15. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, et al. (2014) International Myeloma
Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology 15: e538–
e548. doi: 10.1016/S1470-2045(14)70442-5 PMID: 25439696
16. Meier A, Bagchi A, Sidhu HK, Alter G, Suscovich TJ, et al. (2008) Upregulation of PD-L1 on monocytes
and dendritic cells by HIV–1 derived TLR ligands. AIDS 22: 655–658. PMID: 18317010
17. Gilliet M, CaoW, Liu YJ (2008) Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and
autoimmune diseases. Nat Rev Immunol 8: 594–606. doi: 10.1038/nri2358 PMID: 18641647
PDL1 Expression, on DCs and Myeloma Cells
PLOS ONE | DOI:10.1371/journal.pone.0139867 October 7, 2015 8 / 8
